Abstract

Mesenchymal stem cells (MSCs) can self‐renew and differentiate into multiple cell types. The delivery of drugs to MSCs is an important tool in the emerging fields of tissue regeneration and engineering. In this study, we determined the anticancer efficiency of DQAsomes, which displayed affinity toward human adipose‐derived mesenchymal stem cells (AD‐MSCs). Cytotoxicity assays were conducted to examine human AD‐MSCs. We also evaluated the cellular effects of human AD‐MSCs treated with DQAsomes by cell cycle distribution analysis, annexin‐V propidium iodide staining, and H2DCFDA and found that DQAsomes promoted the differentiation of AD‐MSCs into osteoblast cells. Furthermore, flow cytometry analysis revealed that human AD‐MSCs treated with DQAsomes maintained the phenotypic characteristics of human AD‐MSCs. We demonstrated that DQAsomes can be used in tissue engineering and have clinical relevance as effective drug and protein delivery systems.